Linked Life Data

12864880

Source:http://linkedlifedata.com/resource/pubmed/id/12864880

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
83
pubmed:dateCreated
2003-7-16
pubmed:abstractText
The leading cause of end-stage renal disease (ESRD) is diabetic nephropathy. Interventions that prevent or palliate renal disease have a positive impact by improving patient care and diminishing healthcare costs. The following review summarizes clinical trals that evaluated treatment in various patient populations including Type 2 diabetic patients with microalbuminuria, subjects with proteinuric non-diabetic nephropathies, and Type 1 and Type 2 diabetic patients with overt nephropathy. These clinical trials have demonstrated that agents directly affecting the renin-angiotensin-aldosterone system provide renal protection beyond that attributable to blood pressure control.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0098-6577
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S77-85
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
pubmed:affiliation
Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. bmbrenner@bics.bwh.harvard.edu
pubmed:publicationType
Journal Article, Review